



AHD Implementation in Uganda: Strengthening the M&E of AHD Systems

Dr. Arinaitwe Ivan MoH/ACP, SPO – DSD 14 November 2023

CQUIN 7th Annual Meeting November 13 – 17, 2023 | Johannesburg, South Africa




Outline


- Overview of the HIV Program
- AHD capability maturity model results 2023
- AHD M&E framework
- AHD implementation current status
- Challenges and solutions
- Proposed HMIS tools for AHD



Overview of the HIV Program in Uganda


HIV Prevalence, UPHIA 2020-21







Current State of the HIV Epidemic





Overview of the HIV Program in Uganda - 95 95 95 Achievements

PLHIV Virally suppressed Know status On ART 72 72 All Age groups Adults 15 yrs + **Adult Females Adult Males** Children 0 - 14 yrs


Population Cascade

COUIN

NETWOR

ICap

Conditional Cascade



CQUIN AHD Capability Maturity Model Results, 2023

Policies	
Guidelines	
AHD Scale-up Plan	
SOPs	
Coordination	
ROC Engagement	
Training	Diagnostic Capability 1
Facility Coverage	Client Coverage 1
Supply Chain	Client Coverage 2
M&E System	Client Coverage 3
Quality	Client Coverage 4
Most mature domain	

Most mature domains

Least mature domains

- All AHD CMM domains except Impact were staged light or dark green
- The light greens are a target for improvement as the country improves on stocks for AHD commodities



Trends in the CQUIN AHD Capability Maturity Model Results

2021	2023	
		T 10
		7
		1
		•
		2021 2023

Gaps identified and addressed:

- CD4 testing challenges
- Low facility coverage of diagnostics
 - Inadequate stocks of AHD commodities
 - Comprehensive M&E systems to monitor AHD service delivery




M & E Framework

Indicators	Source	Frequency
Short Term Indicators		
No. of HIV+ patients enrolled at the facility	DHIS II	Quarterly
No. of patients presenting with advanced HIV disease	DHIS II	Quarterly
No. of patients with advanced disease tested with TB LAM	DHIS II	Quarterly
No. of LF-LAM positive patients	DHIS II	Quarterly
No. of LF-LAM positive patients started on TB treatment	DHIS II	Quarterly
No. of patients with advanced disease tested with CrAg	DHIS II	Quarterly
No. of CrAg positive patients	DHIS II	Quarterly
No. of CrAg positive patients started on CCM treatment	DHIS II	Quarterly
No. of HIV+ on TPT	DHIS II	Quarterly
No. of patients being referred to a higher facility	DHIS II	Quarterly
Long Term Indicators		Quarterly
Mortality from AHD		
Mortality from TB among TBHIV co-infected patients	DHIS II	Semi-annually
Treatment Success Rates among TBHIV co-infected patients	DHIS II	Semi-annually
Mortality from CCM among HIV+ patients		Semi-annually
Treatment Success Rates among HIV-CCM co-infected patients		Semi-annually

- Developed during the development of the AHD implementation guidelines in **2019**.
- Stakeholders involved included:- Ministry Of Health, Donor Partners, District Health Teams, Implementing Partners, Health workers and Civil society organizations
- The purpose was to support the stakeholders and service providers at all levels to plan & implement the multi-layered proposed interventions in line with the consolidated HIV guidelines with the aim of reducing HIV related morbidity and mortality in Uganda as a result of Advanced HIV Disease
- **U** The Expected Outcomes included;
- Increase in number of facilities with test kits and treatment commodities
- Increase in proportion of patients screened for AHD
- Increase in proportion of patients successfully treated for AHD (CD4 count <200)



FY2022 AHD identification and treatment among TX_NEW and non suppressed clients



CQUIN 7th Annual Meeting | November 13-17, 2023


NETWORK

Decentralized Testing Services - Advanced HIV Disease/Opportunistic Infections FY23

Key Highlights for new ART clients

Although the performance is still below the 95% target, there has been significant improvement in CD4 access for the newly identified clients (82%)

This has enabled early screening for TB and Cryptococcal meningitis.



Increasing proportions of CD4 tests done Tx New TB LAM Access among TX New patients 70% 70% - 95%

Health Region	Q2	Q3	% Δ
			(Q2-Q1)
Acholi	68%	61%	-7% 🔻
Ankole	49%	63%	14%
Bugisu	53%	62%	9% 🔺
Bukedi	69%	66%	-3% 🔻
Bunyoro	89%	93%	4% 🔺
Busoga	71%	77%	6% 🔺
Kampala	88%	93%	5% 🔺
Karamoja	78%	86%	8% 🔺
Kigezi	82%	83%	1%
Lango	80%	81%	1%
North Buganda	77%	86%	9% 🔺
South Buganda	80%	89%	9% 🔺
Teso	89%	76%	-13% 🔻
Tooro	92%	91%	-1% 🔻
West Nile	88%	94%	6% 🔺
National	76%	82%	6%

Decentralized Testing Services- Advanced HIV Disease/Opportunistic Infections FY23

Key Highlights-Non-suppressed clients at high level viraemia

Although the performance is still below the 95% target, there has been significant improvement in CD4 access for the Non suppressing (73%) Plan to implore Laboratory Community interventions and optimization of patient flows will to improve this cascade

Revised HMIS tools to include non suppressing clients with CD4 below 200

Quarterly AHD performance in the New PLHIV 160% 150% 140% 120% 97% 1.339 100% 93% 87% 86% 1.038 1.392 87% 993 1,358 73% 80% 1,213 58% 60% 46% 40% 17%^{18%} 19% 20% 0% 0% NS Access CD4 NS CD4<200 NS CD4<200 NS with NS with NS with NS CD4<200 NS CD4<200 CD4<200 CD4<200 TB LAM TB LAM CD4<200 CrAg positive CrAg positive Access TB positive positive treated with Access CrAg LAM treated for TB Fluconazole

■Q1 ■Q2

Q3

Low CD4 access consequently affected CrAg and TB LAM Access and as well



Challenges and Mitigation mechanisms

SN	Challenge	Mitigation mechanism
1	Logistics for test kits – CD4, CrAg	 Bi-weekly implementing partner performance review meetings which assist in monitoring stocks in the regions Redistribution of test kits across districts / regions Hub & Spoke model Screening for AHD decentralized to level of health centre 3
2	Missed opportunities among the non-suppressed	 Bi-weekly performance review meetings with accountability for both non-suppressed and new RoC Continuous mentorships and coaching




M&E of AHD in Uganda – Pictorial Digest

Revised AHD Screening tests in the HIV Care Card

	C/	A14		
	Tests and	d Investigat	tions	
	TB LAM	LFTs		
CD4/ CD4%	TB LAMP	RFTs		
	GeneXpert/	Viral Load		
	Truenat	HIV	Date/	
CrAg, RPR	Miscroscopy Xray	Drug	Comobidity Test	
	Others	Resistance		
CD4/CD4%	TB LAM:	LFTs RFTs Done Done	YYYYY HEP B	
CrAg:	TB LAMP	VL date	DD/MM YYYYY HEP C	
RPR	GeneXpert/True nat	VL result VL status	YYYY RFTs	
	Microscopy	dd/mm/yyyy	DD/MM YYYYY LFTs DD/MM RBS/FBS	
	X-Ray:	DR result	DDMM CBC	
Others:	Others:	DR status	DD/MM YYYY Others	

Revised Quarterly reporting indicators – HMIS 106a



Acknowledgements

- MINISTRY OF HEALTH UGANDA
- PEPFAR
- WHO
- UNICEF
- UNAIDS
- CHAI
- EGPAF
- GLOBAL FUND
- ICAP-CQUIN







www.cquin.icap.columbia.edu

Thank you!

